Do analysts recommend OXB or ABC?

Oxford Biomedica currently has a consensus target price of GBX 633.38, suggesting a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities analysts plainly believe Oxford Biomedica is more favorable than Abcam. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Abcam 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, OXB or ABC?

Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oxford Biomedica £168.74M 4.33 -£143.51M -£26.92 N/A Abcam £350.40M 0.00 N/A £0.06 N/A

Which has preferable earnings and valuation, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.10 £7.87M £71.00 29.86 Oxford Biomedica £168.74M 4.33 -£143.51M -£26.92 N/A

Is GNS or OXB more profitable?

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% Oxford Biomedica -17.85% -48.56% -12.67%

Do analysts prefer ERGO or OXB?

Oxford Biomedica has a consensus price target of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Ergomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ergomed 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is ERGO or OXB more profitable?

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity. Company Net Margins Return on Equity Return on Assets Ergomed 9.87% 18.08% 10.16% Oxford Biomedica -17.85% -48.56% -12.67%

Do analysts recommend SLN or OXB?

Oxford Biomedica has a consensus target price of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00

Oxford Biomedica (OXB) Competitors

GBX 603.19 -4.81 (-0.79%)

As of 12:44 PM Eastern

Compare

OXB vs. ABC, GNS, ONT, ERGO, and SLN

Should you buy Oxford Biomedica stock or one of its competitors? MarketBeat compares Oxford Biomedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Biomedica include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Abcam?

Oxford Biomedica (LON:OXB) and Abcam (LON:ABC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Oxford Biomedica currently has a consensus target price of GBX 633.38, suggesting a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities analysts plainly believe Oxford Biomedica is more favorable than Abcam.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Abcam	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Biomedica's average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
Abcam	Neutral

Abcam has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Abcam's return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
Abcam	N/A	N/A	N/A

Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

32.4% of Oxford Biomedica shares are owned by institutional investors. 34.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Abcam beats Oxford Biomedica on 6 of the 11 factors compared between the two stocks.

How does Oxford Biomedica compare to Genus?

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

52.2% of Genus shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 0.7% of Genus shares are held by company insiders. Comparatively, 34.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Genus' average media sentiment score of 0.37 beat Oxford Biomedica's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Overall Sentiment
Genus	Neutral
Oxford Biomedica	Neutral

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.10	£7.87M	£71.00	29.86
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

Genus currently has a consensus price target of GBX 3,216.67, suggesting a potential upside of 51.73%. Oxford Biomedica has a consensus price target of GBX 633.38, suggesting a potential upside of 5.00%. Given Genus' higher possible upside, equities analysts plainly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Summary

Genus beats Oxford Biomedica on 10 of the 14 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.82	-£175.21M	-£15.10	N/A
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

Oxford Nanopore Technologies has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

16.4% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Comparatively, 34.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies currently has a consensus price target of GBX 212.60, indicating a potential upside of 92.05%. Oxford Biomedica has a consensus price target of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Nanopore Technologies' higher possible upside, equities analysts plainly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Oxford Nanopore Technologies had 4 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Oxford Nanopore Technologies and 0 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.58 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Oxford Biomedica	Neutral

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Summary

Oxford Nanopore Technologies and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Ergomed (LON:ERGO) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

71.1% of Ergomed shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 18.2% of Ergomed shares are owned by company insiders. Comparatively, 34.8% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oxford Biomedica has a consensus price target of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ergomed has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Ergomed has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market.

In the previous week, Ergomed's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
Oxford Biomedica	Neutral

Summary

Ergomed beats Oxford Biomedica on 7 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	N/A	N/A	N/A
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Oxford Biomedica has a consensus target price of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Silence Therapeutics has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Silence Therapeutics	Neutral
Oxford Biomedica	Neutral

32.4% of Oxford Biomedica shares are held by institutional investors. 34.8% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Oxford Biomedica beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OXB vs. The Competition

Export

Metric	Oxford Biomedica	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£730.09M	£513.35M	£6.82B	£2.79B
Dividend Yield	4.57%	3.90%	2.67%	6.16%
P/E Ratio	-22.41	3.15	27.00	368.25
Price / Sales	4.33	6,249.85	519.38	84,392.87
Price / Cash	3.01	13.13	26.68	27.89
Price / Book	8.91	87.68	10.67	7.59
Net Income	-£143.51M	-£96.07M	£3.60B	£5.89B
7 Day Performance	-7.06%	-0.65%	-0.32%	0.05%
1 Month Performance	0.53%	1.15%	1.88%	-0.66%
1 Year Performance	60.85%	60.60%	25.50%	62.48%

Oxford Biomedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OXB Oxford Biomedica	1.0494 of 5 stars	GBX 603.19 -0.8%	GBX 633.38 +5.0%	+64.3%	£730.09M	£168.74M	N/A	891
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	3.4941 of 5 stars	GBX 2,054 +0.2%	GBX 3,216.67 +56.6%	-10.5%	£1.36B	£672M	28.93	480
ONT Oxford Nanopore Technologies	3.358 of 5 stars	GBX 119.20 +3.9%	GBX 218.60 +83.4%	-26.1%	£1.16B	£223.90M	N/A	1,281	Analyst Downgrade
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oxford Biomedica (OXB) Competitors

OXB vs. ABC, GNS, ONT, ERGO, and SLN

How does Oxford Biomedica compare to Abcam?

Summary

How does Oxford Biomedica compare to Genus?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Summary

How does Oxford Biomedica compare to Ergomed?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oxford Biomedica (OXB) Competitors

OXB vs. ABC, GNS, ONT, ERGO, and SLN

How does Oxford Biomedica compare to Abcam?

Do analysts recommend OXB or ABC?

Does the media favor OXB or ABC?

Is OXB or ABC more profitable?

Which has higher valuation and earnings, OXB or ABC?

Do institutionals & insiders have more ownership in OXB or ABC?

Summary

How does Oxford Biomedica compare to Genus?

Do institutionals and insiders have more ownership in GNS or OXB?

Does the media prefer GNS or OXB?

Which has preferable earnings and valuation, GNS or OXB?

Do analysts rate GNS or OXB?

Which has more volatility and risk, GNS or OXB?

Is GNS or OXB more profitable?

Summary

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Which has preferable valuation and earnings, ONT or OXB?

Which has more volatility and risk, ONT or OXB?

Do insiders & institutionals hold more shares of ONT or OXB?

Do analysts prefer ONT or OXB?

Does the media prefer ONT or OXB?

Is ONT or OXB more profitable?

Summary

How does Oxford Biomedica compare to Ergomed?

Do institutionals & insiders hold more shares of ERGO or OXB?

Do analysts prefer ERGO or OXB?

Which has higher valuation & earnings, ERGO or OXB?

Is ERGO or OXB more profitable?

Which has more risk and volatility, ERGO or OXB?

Does the media prefer ERGO or OXB?

Summary

How does Oxford Biomedica compare to Silence Therapeutics?

Is SLN or OXB more profitable?

Do analysts recommend SLN or OXB?

Which has stronger earnings and valuation, SLN or OXB?

Does the media favor SLN or OXB?

Do insiders & institutionals hold more shares of SLN or OXB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXB vs. The Competition

Oxford Biomedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools